Study summary
I-DXd shrank about 1 in 5 heavily treated tumors
21%of tumors shrank, 6 of 28 people
What was tested
I-DXd (ifinatamab deruxtecan), an antibody-drug conjugate aimed at B7-H3, in people who had already had several treatments. No comparison group.
What they found
- Tumors shrank in 6 of 28 people (21%). Responses lasted about 3.5 months.
- Typical survival was 7.0 months.
- In small cell lung cancer the same drug shrank 11 of 21 tumors (52%).
What it means
A modest signal in a very hard-to-treat group. The 510-person worldwide phase 3 will show whether it beats chemotherapy.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.